GT Biopharma Inc Dossier
Qualitative Analysis
Business overview
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage immuno-oncology company focused on the development and commercialization of novel therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE®) platform. Licensed from the University of Minnesota, the TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient's own natural killer (NK) cells. The platform connects NK cells to specific cancer targets while delivering a built-in interleukin-15 (IL-15) signal to support NK-cell expansion and persistence. The company's active clinical pipeline includes GTB-3650, which is in a Phase 1 trial for CD33-expressing hematologic malignancies (such as acute myeloid leukemia and high-risk myelodysplastic syndrome), and GTB-5550, a B7-H3-targeted NK cell engager in a Phase 1 trial for solid tumors. Effective July 1, 2024, GT Biopharma transitioned to a fully remote operating model.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiation of a Phase 1 dose-escalation basket trial evaluating GTB-5550, a B7-H3-targeted natural killer (NK) cell engager, in patients with advanced solid tumors. This represents the company's first clinical expansion beyond hematological malignancies into solid tumors.
Expected impact: Establishes clinical proof-of-concept for subcutaneous delivery of a dual nanobody TriKE® in a $362 billion global solid tumor market.
Broader implementation of AI-based computational tools into the discovery and engineering of tumor-targeting engagers and multi-domain proteins to optimize sequence, structural stability, linker design, and spatial architecture.
Expected impact: Improves pipeline discovery efficiencies and accelerates the development of next-generation TriKE® assets.
Ongoing Phase 1 dose-escalation study evaluating GTB-3650 for relapsed or refractory CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Expected impact: Aims to demonstrate clinical safety and early efficacy signals as dosing levels reach predicted therapeutic thresholds.